Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares: 2014-2024

Historic Treasury Shares for Iovance Biotherapeutics (IOVA) over the last 5 years, with Dec 2024 value amounting to $9.5 million.

  • Iovance Biotherapeutics' Treasury Shares fell 0.31% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 0.31%. This contributed to the annual value of $9.5 million for FY2024, which is 176.43% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Treasury Shares stood at $9.5 million for FY2024, which was up 176.43% from $3.5 million recorded in FY2023.
  • Iovance Biotherapeutics' Treasury Shares' 5-year high stood at $9.5 million during FY2024, with a 5-year trough of $3.5 million in FY2023.
  • Its 2-year average for Treasury Shares is $6.5 million, with a median of $6.5 million in 2023.
  • Data for Iovance Biotherapeutics' Treasury Shares shows a peak YoY spiked of 176.43% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Treasury Shares (Yearly) stood at $3.5 million in 2023, then soared by 176.43% to $9.5 million in 2024.